神经退行性疾病中氧化应激的双重攻击:MAO-B和Nrf2作为选定的目标
Filippo Basagni1, Maria Luisa Di Paolo2, Giorgio Cozza2
1Department of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy.
Molecules (Basel, Switzerland)
|November 14, 2023
概括
研究人员开发了一种具有强大的抗氧化和神经保护性质的新型皮奥格利塔衍生物,针对阿尔茨海默氏症和帕金森氏症等神经退行性疾病中的氧化应激和神经炎症.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
背景情况:
- 神经退行性疾病,包括阿尔茨海默氏症和帕金森病,是由氧化应激和神经炎症驱动的.
- 目前针对这些疾病的治疗方法仍然不够,这凸显了对新型治疗策略的需求.
- 抗糖尿病药物皮奥格利塔因其MAO-B抑制活性而显示出作为神经保护剂的前景.
研究的目的:
- 通过结合抗氧化功能来增强皮奥格利塔的神经保护性.
- 开发具有直接和间接抗氧化特性的新型化合物,准Nrf2通路激活和激素清除.
- 为了确定在神经退行性疾病中潜在的治疗应用的强效和选择性MAO-B抑制剂.
主要方法:
- 合成和选的pioglitazone衍生物对MAO-B抑制性质.
- 对MAO-A的选择性进行评估的化合物.
- 评估了化合物的激活Nrf2通路和降低活性氧物种 (ROS) 水平的能力.
主要成果:
- 一种咖啡酸衍生物 (化合物2) 证明了具有可逆机制的强大和选择性MAO-B抑制.
- 化合物2有效地激活了Nrf2通路,由增加的Nrf2核转移证明.
- 该衍生品在生理和压力条件下显著降低了ROS含量,表明强大的抗氧化能力.
结论:
- 修改后的pioglitazone支架表现出显著的抗氧化特性,使其成为开发新疗法的有希望的起点.
- 开发的化合物显示了通过减轻氧化应激和神经炎症来治疗神经退行性疾病的潜力.
- 需要进一步的研究,以充分阐明这种新型药物的神经保护机制和治疗疗效.
相关概念视频
01:46Electron Transport Chain: Complex I and II
14.2K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
14.2K
01:29Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
01:23Antidepressant Drugs: MAOIs and Other Agents
252
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
252
01:24Parkinson's Disease: Treatment
281
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
281
01:22Alzheimer's Disease: Treatment
197
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
197